Category: AL amyloidosis

  • AZ claims full control of Caelum’s AL amyloidosis drug in $500m deal

    AstraZeneca’s newly acquired Alexion will buy the remaining equity in rare disease specialist Caelum Biosciences in a deal that could be worth up to $500 million. The deal gives the Anglo-Swedish drugmaker complete control of Caelum’s late-stage medicine for light chain (AL) amyloidosis, a potentially fatal disease that causes the rogue protein amyloid to build […]

  • J&J’s Darzalex Faspro is first US therapy for rare blood disorder

    Johnson & Johnson’s Darzalex Faspro has become the first product approved by the FDA to treat light chain (AL) amyloidosis, a rare and often fatal blood cell disorder. The new indication is the second for Darzalex Faspro, a subcutaneous version of blockbuster intravenous therapy Darzalex (daratumumab) which is used to treat multiple myeloma on its […]